From Johnson & JohnsonSep 24 2024 Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthenia gravis (gMG). The application included data from the Phase 3 Vivacity-MG3 study...